Alterations in cholesterol absorption/synthesis markers characterize Framingham offspring study participants with CHD
- PMID: 19436064
- PMCID: PMC2724787
- DOI: 10.1194/jlr.P900039-JLR200
Alterations in cholesterol absorption/synthesis markers characterize Framingham offspring study participants with CHD
Abstract
Data is limited on measures influencing cholesterol homeostasis in subjects at high risk of developing cardiovascular disease (CVD) relative to established risk factors. To address this, we quantified circulating indicators of cholesterol homeostasis (plasma phytosterols and cholesterol precursor concentrations as surrogate measures of cholesterol absorption and synthesis, respectively) in Framingham Offspring Study Cycle-6 participants diagnosed with established CVD and/or >or=50% carotid stenosis not taking lipid lowering medication (cases, N = 155) and matched controls (N = 414). Cases and controls had similar plasma LDL-cholesterol; HDL-cholesterol was significantly lower in males, while triglyceride concentrations were significantly higher in female cases relative to their respective controls. Cholesterol absorption markers were significantly higher (229 +/- 7 vs. 196 +/- 4, 169 +/- 6 vs. 149 +/- 3 and 144 +/- 5 vs. 135 +/- 3 for campesterol, sitosterol, and cholestanol, respectively), whereas cholesterol synthesis markers were significantly lower (116 +/- 4 vs. 138 +/- 3, 73 +/- 3 vs. 75 +/- 2 for lathosterol and desmosterol, respectively) in cases compared with controls, irrespective of sex. After controlling for standard risk factors, campesterol (2.47 [1.71-3.56]; P < 0.0001), sitosterol (1.86 [1.38-2.50]; P < 0.0001), cholestanol (1.57 [1.09-2.27]; P = 0.02), desmosterol (0.59 [0.42-0.84]; P = 0.003), and lathosterol (0.58 [0.43-0.77]; P = 0.0002) were significantly associated with CVD (odds ratio [95% confidence interval]). These data suggest that impaired cholesterol homeostasis, reflected by lower synthesis and higher absorption marker concentrations, are highly significant independent predictors of prevalent CVD in this study population.
Figures


Similar articles
-
Sex-specific differences in the predictive value of cholesterol homeostasis markers and 10-year cardiovascular disease event rate in Framingham Offspring Study participants.J Am Heart Assoc. 2013 Feb 19;2(1):e005066. doi: 10.1161/JAHA.112.005066. J Am Heart Assoc. 2013. PMID: 23525441 Free PMC article.
-
Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects.Atherosclerosis. 2011 Dec;219(2):761-7. doi: 10.1016/j.atherosclerosis.2011.09.017. Epub 2011 Sep 16. Atherosclerosis. 2011. PMID: 21982411 Clinical Trial.
-
The relationships of cholesterol metabolism and plasma plant sterols with the severity of coronary artery disease.J Lipid Res. 2009 Feb;50(2):334-41. doi: 10.1194/jlr.P800013-JLR200. Epub 2008 Sep 3. J Lipid Res. 2009. PMID: 18769018
-
Diurnal Variation of Markers for Cholesterol Synthesis, Cholesterol Absorption, and Bile Acid Synthesis: A Systematic Review and the Bispebjerg Study of Diurnal Variations.Nutrients. 2019 Jun 26;11(7):1439. doi: 10.3390/nu11071439. Nutrients. 2019. PMID: 31247945 Free PMC article.
-
[Change in the cholesterol metabolism associated with the combined inhibition of synthesis and absorption].Orv Hetil. 2007 Apr 8;148(14):627-32. doi: 10.1556/OH.2007.28065. Orv Hetil. 2007. PMID: 17403635 Review. Hungarian.
Cited by
-
The effects of vitamin E or lipoic acid supplementation on oxyphytosterols in subjects with elevated oxidative stress: a randomized trial.Sci Rep. 2017 Nov 10;7(1):15288. doi: 10.1038/s41598-017-15615-y. Sci Rep. 2017. PMID: 29127425 Free PMC article. Clinical Trial.
-
Phytosterol intake and risk of coronary artery disease: Results from 3 prospective cohort studies.Am J Clin Nutr. 2024 Feb;119(2):344-353. doi: 10.1016/j.ajcnut.2023.11.020. Epub 2023 Dec 1. Am J Clin Nutr. 2024. PMID: 38042410 Free PMC article.
-
Cardiovascular Disease Prevention: The Earlier the Better? A Review of Plant Sterol Metabolism and Implications of Childhood Supplementation.Int J Mol Sci. 2019 Dec 24;21(1):128. doi: 10.3390/ijms21010128. Int J Mol Sci. 2019. PMID: 31878116 Free PMC article. Review.
-
Cholesterol absorption status and fasting plasma cholesterol are modulated by the microsomal triacylglycerol transfer protein -493 G/T polymorphism and the usual diet in women.Genes Nutr. 2011 Feb;6(1):71-9. doi: 10.1007/s12263-010-0174-x. Epub 2010 Apr 1. Genes Nutr. 2011. PMID: 21437032 Free PMC article.
-
Plant Sterol-Enriched Palm Oil Intervention to Improve Lipid Profile and Inflammation Status in Hyperlipidemic Individuals.Nutrients. 2024 Oct 3;16(19):3370. doi: 10.3390/nu16193370. Nutrients. 2024. PMID: 39408337 Free PMC article. Clinical Trial.
References
-
- National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. 2002. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 106: 3143–3421. - PubMed
-
- Baigent C., Keech A., Kearney P. M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., et al. for Cholesterol Treatment Trialists' (CTT) Collaborators. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 366: 1267–1278. - PubMed
-
- Heart Protection Study Collaborative Group. 2002. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 360: 23–33. - PubMed
-
- Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. 1998. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339: 1349–1357. - PubMed
-
- Nakamura H., Arakawa K., Itakura H., Kitabatake A., Goto Y., Toyota T., Nakaya N., Nishimoto S., Muranaka M., Yamamoto A., et al. MEGA Study Group. 2006. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 368: 1155–1163. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical